What Was Normal Blood Pressure in 1970?

In 1970, a blood pressure reading that would alarm a doctor today was often considered perfectly acceptable. The formal threshold for diagnosing hypertension hovered around 160/95 mmHg or higher, and many clinicians did not start drug treatment unless the bottom number (diastolic pressure) reached 100 mmHg or above. A widely used rule of thumb held that “normal” systolic pressure was 100 plus the patient’s age, meaning a 70-year-old could walk around with a systolic reading of 170 mmHg and be told everything was fine. The gap between that era and today’s guidelines, which flag readings above 130/80 mmHg as high, reflects one of the biggest shifts in modern cardiovascular medicine.

The “100 Plus Your Age” Rule

One of the most striking things about mid-twentieth-century blood pressure medicine is just how casually rising pressure was treated. At the start of the Framingham Heart Study, a prevailing idea in clinical practice was that systolic blood pressure naturally goes up with age, and that the expected “normal” value for any person was roughly 100 plus their age in years.¹ A 50-year-old with a reading of 150 mmHg systolic? Normal. A 65-year-old at 165? Expected. The reasoning was essentially that arteries stiffen with age, so higher pressure is the body’s way of pushing blood through narrower pipes. Treating it would be treating the body’s natural compensation.

This was not a fringe belief. It was mainstream medical teaching. The Framingham researchers would eventually demolish it by following thousands of residents of Framingham, Massachusetts for decades and showing that cardiovascular risk climbs steadily with blood pressure at every age. But in 1970, that evidence was still accumulating, and many practicing doctors clung to the older view.²

Why Doctors Cared Almost Exclusively About the Bottom Number

Even among physicians who took high blood pressure seriously in 1970, the focus was almost entirely on diastolic pressure, the lower of the two numbers in a reading. The thinking was that diastolic pressure reflects the constant strain on artery walls between heartbeats, making it the more meaningful indicator of long-term vascular damage. Systolic pressure, the upper number, was seen as more variable and less clinically important. This was so deeply entrenched that most clinical trials of the era enrolled patients based on diastolic readings alone and barely analyzed systolic data.

A later review of the evidence found that observational studies had actually shown equal or greater risk from elevated systolic pressure all along, and even some of the clinical trials themselves, when re-analyzed after the fact, showed systolic pressure was a better predictor of heart disease death than diastolic pressure.³ In other words, the medical profession was focused on the less informative number for decades. The diastolic fixation persisted well into the 1990s for many practitioners, and it took repeated waves of evidence before isolated systolic hypertension, high systolic pressure with normal diastolic pressure, was recognized as a distinct and dangerous condition worth treating on its own.

This mattered enormously for older adults. Systolic pressure tends to climb with age while diastolic pressure often levels off or even drops after around age 55. Under the diastolic-only framework, an older person could have dangerously high systolic pressure and still be told they were fine because the bottom number looked acceptable.

The VA Trials That Began Changing the Conversation

The strongest push toward treating high blood pressure with drugs came from a pair of studies run through the Veterans Administration (VA) in the late 1960s and 1970. The first phase, completed in 1967, looked at patients with severely elevated diastolic pressure (averaging 115 to 129 mmHg) and found such dramatic benefits from treatment that the trial was stopped early. The second phase, published in 1970, enrolled 380 men with moderately elevated diastolic pressure, averaging 90 to 114 mmHg, and randomly assigned them to receive either blood pressure medication or a placebo.⁴

The results were stark. Over roughly five years of follow-up, the estimated risk of a serious cardiovascular event dropped from about 55% in the untreated group to about 18% in the treated group. Thirty-five men in the control group suffered a major event compared to nine in the treatment group. Nineteen deaths related to hypertension or atherosclerosis occurred among untreated men versus eight among those on medication.⁴ The treatment itself used a combination including a thiazide diuretic, and it achieved an average diastolic drop of about 19 mmHg.⁵

These VA studies were genuinely landmark. They provided the first randomized-trial evidence that treating moderately high diastolic pressure saved lives and prevented strokes and heart attacks. But they also reinforced the diastolic-centric worldview, because that was the measure the trials were designed around. And critically, the studies involved only men, and almost exclusively hospitalized veterans, so the implications for women and for the general population were left unaddressed for years to come.⁶

Insurance Companies Knew Earlier Than Doctors

Here is one of the more underappreciated details of this era: life insurance actuaries had identified the dangers of elevated blood pressure long before most clinicians took it seriously. By the early 1970s, follow-up studies of insured people spanning nearly 50 years had established that untreated readings above 140/90 mmHg were associated with significant excess mortality. Men under 40 with casual blood pressures around 150/100 mmHg died at roughly three times the rate of standard insured risks. Men 40 and older with the same readings died at about two and a quarter times the expected rate.⁷

The insurance data also pointed to something that the medical profession was slow to accept: the blood pressures associated with the longest life were well below what doctors were calling “normal.” The actuarial evidence suggested optimal pressures were below 110 mmHg systolic and 70 mmHg diastolic, numbers that many physicians in 1970 would have considered unnecessarily low or even cause for concern.⁷ The gap between what insurance companies considered risky (anything above 140/90) and what the medical profession considered worth treating (often not until diastolic exceeded 100) left a large group of people in a no-man’s land: too high for optimal longevity, not high enough for their doctor to intervene.

What a Real Patient Looked Like in 1970s Clinics

Data from the Veterans Administration Hypertension Screening and Treatment Program offers a window into what blood pressure readings actually looked like among patients identified as hypertensive in the mid-1970s. Across 32 VA clinics between 1974 and 1976, nearly 12,000 male veterans were flagged as having high blood pressure. Their average pretreatment reading was about 154/101 mmHg, and their mean age was around 52 or 53.⁸ That average diastolic of 101 mmHg sat right at the treatment threshold that was conventional at the time. Over about one in ten of these men had systolic readings above 180 mmHg, a level that would prompt urgent treatment today but was not the primary diagnostic concern then.

What happened to these men over the long term underscores the cost of the era’s high thresholds. During a minimum of nearly 14 years of follow-up, roughly 45% of the group died. Two hundred forty-five developed end-stage kidney disease.⁸ Many of these outcomes would likely have been preventable under modern treatment standards, which call for intervention at lower thresholds and tighter control targets.

How Blood Pressure Was Measured in the 1970s

Every blood pressure reading in the early 1970s was taken manually, using a mercury sphygmomanometer and a stethoscope. A cuff was inflated around the upper arm, then slowly deflated while the examiner listened for specific sounds in the brachial artery. The systolic reading was marked when the first sound appeared; the diastolic reading was recorded when the sounds disappeared. This method required training, good hearing, and careful technique, and it was subject to substantial observer variation. Two different clinicians could get meaningfully different readings on the same patient, and the phenomenon of “white coat hypertension,” readings elevated by the anxiety of being in a medical setting, was not yet a recognized diagnostic concern.

Automated oscillometric blood pressure devices, the kind now found in every pharmacy and most home monitoring kits, were developed in the 1970s precisely to address some of these limitations. The first commercially available automated device, the DINAMAP 825, hit the market in 1976.⁹ But adoption was slow, and for most of the decade, blood pressure measurement remained a manual, operator-dependent process. This matters because it means the “normal” readings of the era were filtered through a method that introduced more variability and potential error than today’s standardized approaches.

The First Official Guidelines Arrived in 1977

It may surprise people to learn that there was no official, unified guideline for diagnosing and treating high blood pressure in the United States until the very end of the 1970s. Before 1977, decisions about when to treat were guided by individual clinical judgment, local institutional protocols, and evolving (but informal) consensus from study results. The threshold that was most widely accepted through the early and mid-1970s was a diastolic reading of 100 mmHg or above, a cutoff that the British Cardiac Society formally endorsed in 1976.¹⁰

In 1977, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (known as the JNC) issued the first comprehensive United States guideline. This was a product of the National High Blood Pressure Education Program, launched in 1972, which was itself a response to the VA trial results and growing epidemiological evidence.¹⁰ By the end of the decade, the formal hypertension threshold was set at 160/95 mmHg.¹⁰ Anything below that was, officially, not hypertension. Compare that to today’s American Heart Association threshold of 130/80 mmHg, and you can see that a reading of, say, 145/92 went from “perfectly normal” in 1977 to “Stage 2 hypertension requiring medication” in 2017.

How Thresholds Kept Dropping Decade by Decade

The story after 1977 is one of steadily falling cutoffs as evidence accumulated. The original JNC guideline set the bar at 160/95. Subsequent JNC revisions lowered the definition to 140/90 mmHg, where it remained for several decades. Then, in 2017, the American College of Cardiology and the American Heart Association dropped the threshold again to 130/80 mmHg, reclassifying tens of millions of previously “normal” Americans as hypertensive overnight.

The push toward even lower targets got a major boost from the SPRINT trial, which showed that targeting a systolic pressure below 120 mmHg rather than below 140 mmHg reduced cardiovascular events by about 25% in people at elevated risk.¹¹ The patients who benefited most were not the general population but a select subset, roughly 20 to 30% of all people with hypertension, who had elevated cardiovascular risk from various causes.¹² Still, SPRINT reinforced the broader lesson that lower is generally better for blood pressure, a radical reversal from the “100 plus your age” philosophy that prevailed just a few decades earlier.

The Global Cost of Changing the Numbers

Every time a guideline lowers the blood pressure threshold, the number of people classified as hypertensive jumps. This is not just a paperwork issue. It has real implications for how many people are told they need medication, how healthcare systems allocate resources, and how individuals think about their own health.

A large international analysis of over four million participants found that moving the diagnostic threshold from 140/90 down to 130/80 mmHg increased the rate of hypertension by a median of about 72% across participating countries. Moving it even lower, to 120/70, more than doubled the hypertension rate in most settings. The effect was most dramatic in low-income countries, where a shift to 130/80 increased hypertension prevalence by about 95%, compared to about 72% in high-income countries.¹³

This does not mean the lower thresholds are wrong. It means that guideline changes do not just reflect medical knowledge; they reshape entire healthcare systems. In 1970, a blood pressure of 150/92 qualified you as healthy. By 2020, that same reading in many countries would prompt a conversation about lifestyle changes and possibly medication. Both of those clinical responses were considered the correct standard of care in their respective eras. The science got sharper, but each adjustment swept millions of additional people into the “needs treatment” category, and not every healthcare system was equipped to handle the increased demand.

Why “Mild” Hypertension Was Dismissed for So Long

One of the lasting misconceptions that the Framingham Study helped dismantle was the idea that mildly elevated blood pressure was essentially harmless. In 1970, the clinical consensus treated blood pressure as a threshold problem: below a certain cutoff you were safe, above it you were at risk. The notion that risk increases continuously, with no safe harbor, was not yet established in practice. Readings in the range of 140 to 160 systolic and 90 to 100 diastolic were often described as “borderline” or “labile” and were not considered worthy of treatment.

Framingham data challenged this directly, showing that people in that borderline range still had meaningfully elevated rates of heart attack, stroke, and heart failure compared to those with lower readings.² The problem was that “mild” sounds benign, and both patients and doctors were reluctant to medicalize a reading that did not feel dangerous. It took decades of longitudinal data to convince the profession that the word “mild” was misleading, that hypertension’s damage is cumulative, and that decades of slightly elevated pressure can be just as destructive as a shorter period of very high readings.

Salt, Kidneys, and the Evolutionary Mismatch

The underlying biology of essential hypertension, the kind with no identifiable single cause, which accounts for about 90% of all cases, was being debated in the 1970s and remains an area of active research. One influential framework centers on the kidney’s ability to excrete sodium. From an evolutionary perspective, humans are adapted to consume and excrete less than about one gram of sodium per day. Modern diets in industrialized countries far exceed that amount, and the theory holds that essential hypertension develops when the kidneys cannot excrete the sodium being ingested without raising blood pressure to force the excess out.¹⁴

This kidney-centered model helps explain why blood pressure tends to rise with age in societies that eat processed, salt-heavy diets but stays low in populations with minimal salt intake. It also partly explains why the first effective antihypertensive drugs were thiazide diuretics, which work by helping the kidneys excrete more sodium and water. In the 1970s, these diuretics were the backbone of treatment, and they remain a first-line option today, which is a rare instance of continuity in a field that has otherwise undergone dramatic revision.

The broader implication is that rising blood pressure with age is not an inevitable feature of human biology. It is a feature of human diets and lifestyles. That distinction was not widely appreciated in 1970, when the “100 plus your age” formula treated age-related increases as normal physiology rather than a modifiable disease process. The shift from accepting rising pressure as natural to treating it as pathological is, in many ways, the single biggest conceptual change in blood pressure medicine over the past half-century.

1
American Heart Journal. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile
2
Journal of Human Hypertension. Fifty years of Framingham Study contributions to understanding hypertension
3
Journal of Clinical Epidemiology. A historical perspective of elevated systolic vs diastolic blood pressure from an epidemiological and clinical trial viewpoint
4
JAMA. Effects Morbidity of Treatment on in Hypertension: II. Results in Patients With Diastolic Blood Pressure Averaging 90 Through 114 mm Hg
5
Frontiers in Cardiovascular Medicine. Timeline of History of Hypertension Treatment
6
PubMed Central. Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective
7
The American Journal of Medicine. High blood pressure, other risk factors and longevity: The insurance viewpoint
8
PubMed. Early predictors of 15-year end-stage renal disease in hypertensive patients
9
Nature. Automated ‘oscillometric’ blood pressure measuring devices: how they work and what they measure
10
PubMed Central. The Evolution of Blood Pressure Thresholds and Targets over Time: A Historical Review
11
PubMed. Systolic Blood Pressure Intervention Trial (SPRINT) and Target Systolic Blood Pressure in Future Hypertension Guidelines
12
Nature Reviews Cardiology. Has the SPRINT trial introduced a new blood-pressure goal in hypertension?
13
PubMed. Global Impact of Different Blood Pressure Thresholds in 4 021 690 Participants of the May Measurement Month Initiative
14
PubMed Central. Essential hypertension: an approach to its etiology and neurogenic pathophysiology